- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Hepatitis E Vaccine Provides Long-term Protection
![Hepatitis E Vaccine Provides Long-term Protection Hepatitis E Vaccine Provides Long-term Protection](https://medicaldialogues.in/h-upload/2023/08/08/750x450_215925-hepatitis-b.webp)
Hepatitis E virus (HEV) is a common cause of acute hepatitis, yet its prevention often receives less attention compared to other hepatitis viruses. Understanding the long-term effectiveness of hepatitis E vaccines is crucial for disease control and prevention efforts.
A recent study conducted in Dongtai County, China, extended a phase-3 clinical trial to evaluate the durability of protection provided by a hepatitis E vaccine over a 10-year period. The initial trial enrolled over 112,000 healthy adults and randomly assigned them to receive either the hepatitis E vaccine or a placebo. This study was published in the journal The Lancet by Shoujie H. and colleagues.
Participants received three doses of the vaccine or placebo intramuscularly at months 0, 1, and 6. A comprehensive surveillance system was established to monitor hepatitis E cases in the study region over the following 10 years. The primary outcome was the efficacy of the vaccine in preventing confirmed cases of hepatitis E occurring at least 30 days after the third dose.
The key findings of the study were:
Over the 10-year study period, 90 cases of hepatitis E were identified, with significantly fewer cases in the vaccine group compared to the placebo group.
The vaccine demonstrated an efficacy of 83.1% in the modified intention-to-treat analysis and 86.6% in the per-protocol analysis.
Moreover, antibody persistence was assessed in subsets of participants, showing that a significant proportion maintained detectable antibody levels even after several years.
The study findings indicate that immunization with the hepatitis E vaccine provides long-lasting protection against hepatitis E, with vaccine-induced antibodies persisting for at least 8.5 years. This underscores the importance of vaccination programs in preventing hepatitis E infections and highlights the effectiveness of the vaccine in reducing disease burden over the long term.
Reference:
Huang, S., Zhang, X., Su, Y., Zhuang, C., Tang, Z., Huang, X., Chen, Q., Zhu, K., Hu, X., Ying, D., Liu, X., Jiang, H., Zang, X., Wang, Z., Yang, C., Liu, D., Wang, Y., Tang, Q., Shen, W., … Xia, N. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet,2024. https://doi.org/10.1016/s0140-6736(23)02234-1
Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751